{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:16:52Z","timestamp":1777897012188,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016061","name":"Stichting de Drie Lichten","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jbo.2026.100751","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:14:12Z","timestamp":1770999252000},"page":"100751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience"],"prefix":"10.1016","volume":"57","author":[{"given":"Tom M.","family":"de Groot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris R.H.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle R","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens P.","family":"te Velde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier Q.","family":"Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik T","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job N.","family":"Doornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"Jutte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Lozano-Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jbo.2026.100751_b0005","first-page":"84","article-title":"Overview of diagnosis and management of metastatic disease to bone","volume":"19","author":"Yu","year":"2012","journal-title":"Cancer Control J. Moffitt Cancer Cent."},{"key":"10.1016\/j.jbo.2026.100751_b0010","first-page":"87","article-title":"Estimated number of prevalent cases of metastatic bone disease in the US adult population","volume":"4","author":"Li","year":"2012","journal-title":"Clin. Epidemiol."},{"issue":"11","key":"10.1016\/j.jbo.2026.100751_b0015","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.22678","article-title":"Economic burden of metastatic bone disease in the U.S","volume":"109","author":"Schulman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2026.100751_b0020","first-page":"335","article-title":"Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States","volume":"7","author":"Hernandez","year":"2015","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.jbo.2026.100751_b0025","unstructured":"Narrative review of the epidemiology, economic burden, and societal impact of metastatic bone disease - DiCaprio - Annals of Joint [Internet]. [cited 2022 Dec 5]. Available from: https:\/\/aoj.amegroups.com\/article\/view\/6807\/html."},{"issue":"20","key":"10.1016\/j.jbo.2026.100751_b0030","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jbo.2026.100751_b0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2106\/JBJS.21.00711","article-title":"Clinical outcome differences in the treatment of impending versus completed pathological long-bone fractures","volume":"104","author":"Groot","year":"2022","journal-title":"JBJS"},{"issue":"13","key":"10.1016\/j.jbo.2026.100751_b0040","doi-asserted-by":"crossref","first-page":"14264","DOI":"10.1002\/cam4.6097","article-title":"Comparison of eight modern preoperative scoring systems for survival prediction in patients with extremity metastasis","volume":"12","author":"Lee","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.jbo.2026.100751_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100682","article-title":"Artificial Intelligence in bone Metastases: a systematic review in guideline adherence of 92 studies","volume":"52","author":"van der Linden","year":"2025","journal-title":"J. Bone Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2026.100751_b0050","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CORR.0000000000000997","article-title":"Development and internal validation of machine learning algorithms for preoperative survival prediction of extremity metastatic disease","volume":"478","author":"Thio","year":"2020","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.jbo.2026.100751_b0055","article-title":"The preoperative machine learning algorithm for extremity metastatic disease can predict 90\u2010day and 1\u2010year survival: an external validation study","author":"Skalitzky","year":"2021","journal-title":"J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2026.100751_b0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CORR.0000000000001969","article-title":"International validation of the SORG machine-learning algorithm for predicting the survival of patients with extremity metastases undergoing surgical treatment","volume":"480","author":"Tseng","year":"2022","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.jbo.2026.100751_b0065","unstructured":"de Groot et al. Does the SORG Algorithm Generalize to a Contemporary Cohort of Patients with Long-Bone Metastases? A Temporal Validation from 2017-2020 with 406 patients. CORR Rev Process."},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: the next generation of cancer treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr. Drug Discov. Technol."},{"issue":"4","key":"10.1016\/j.jbo.2026.100751_b0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7603\/s40681-015-0019-4","article-title":"An overview of targeted cancer therapy","volume":"5","author":"Padma","year":"2015","journal-title":"Biomedicine"},{"key":"10.1016\/j.jbo.2026.100751_b0080","article-title":"Impact of targeted therapy on the survival of patients with advanced-stage non-small cell lung cancer in Oncosalud - AUNA","volume":"29","author":"Aguilar","year":"2022","journal-title":"Cancer Control J. Moffitt Cancer Cent."},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jbo.2026.100751_b0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-3-319-40389-2_8","article-title":"Targeted therapies for lung cancer","volume":"170","author":"Stinchcombe","year":"2016","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.jbo.2026.100751_b0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coph.2016.11.005","article-title":"Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment","volume":"31","author":"Gu","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jbo.2026.100751_b0100","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jbo.2026.100751_b0105","unstructured":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer | NEJM [Internet]. [cited 2022 Dec 22]. Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2112435."},{"key":"10.1016\/j.jbo.2026.100751_b0110","unstructured":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | NEJM [Internet]. [cited 2022 Dec 22]. Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2202809."},{"key":"10.1016\/j.jbo.2026.100751_b0115","unstructured":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM [Internet]. [cited 2022 Dec 22]. Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1910836."},{"issue":"14","key":"10.1016\/j.jbo.2026.100751_b0120","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.3390\/ijms21145009","article-title":"Immunotherapies and combination strategies for immuno-oncology","volume":"21","author":"Barbari","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.jbo.2026.100751_b0125","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/MLR.0000000000001921","article-title":"Association of receipt of systemic treatment for melanoma with insurance type in North Carolina","volume":"61","author":"Adamson","year":"2023","journal-title":"Med. Care"},{"issue":"Suppl 1","key":"10.1016\/j.jbo.2026.100751_b0130","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"10.1016\/j.jbo.2026.100751_b0135","doi-asserted-by":"crossref","DOI":"10.1097\/CORR.0000000000002698","article-title":"Does the SORG machine-learning algorithm for extremity metastases generalize to a contemporary cohort of patients? Temporal validation from 2016 to 2020","author":"de Groot","year":"2023","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.jbo.2026.100751_b0140","doi-asserted-by":"crossref","unstructured":"H. Mirels. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin. Orthop. (415 Suppl) 2003 S4\u2013S13.","DOI":"10.1097\/01.blo.0000093045.56370.dd"},{"issue":"2","key":"10.1016\/j.jbo.2026.100751_b0145","first-page":"679","article-title":"Eastern cooperative oncology group performance score is associated with survival after radiotherapy of bone metastases from prostate cancer","volume":"34","author":"Haus","year":"2020","journal-title":"Vivo Athens Greece"},{"issue":"5","key":"10.1016\/j.jbo.2026.100751_b0150","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/cam4.292","article-title":"New prognostic factors and scoring system for patients with skeletal metastasis","volume":"3","author":"Katagiri","year":"2014","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","article-title":"MissForest\u2013non-parametric missing value imputation for mixed-type data","volume":"28","author":"Stekhoven","year":"2012","journal-title":"Bioinforma Oxf. Engl."},{"key":"10.1016\/j.jbo.2026.100751_b0160","series-title":"Regression Modeling Strategies","author":"Harrel","year":"2024"},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"10","key":"10.1016\/j.jbo.2026.100751_b0170","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jbo.2026.100751_b0175","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.1201","article-title":"Treatment and attrition trends for metastatic clear cell renal cell carcinoma in the US","volume":"8","author":"Ozay","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"20","key":"10.1016\/j.jbo.2026.100751_b0180","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0190","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2026.100751_b0205","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25459","article-title":"Use of first-line immune checkpoint inhibitors and association with overall survival among patients with metastatic melanoma in the anti-PD-1 Era","volume":"5","author":"Lamba","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.jbo.2026.100751_b0210","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jbo.2026.100751_b0215","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1634\/theoncologist.2020-0193","article-title":"Prolonging survival: the role of immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer","volume":"25","author":"Melosky","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12916-021-02070-w","article-title":"The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy","volume":"19","author":"Ramagopalan","year":"2021","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.jbo.2026.100751_b0225","article-title":"HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis","volume":"2","author":"Erickson","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"issue":"3","key":"10.1016\/j.jbo.2026.100751_b0230","first-page":"155","article-title":"Targeted cancer therapies","volume":"103","author":"Smith","year":"2021","journal-title":"Am. Fam. Physician"},{"issue":"4","key":"10.1016\/j.jbo.2026.100751_b0235","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/jcm9041063","article-title":"Comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials","volume":"9","author":"Hoang","year":"2020","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.jbo.2026.100751_b0240","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5806","article-title":"Comparative survival associated with use of targeted vs nontargeted therapy in medicare patients with metastatic renal cell carcinoma","volume":"2","author":"Li","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jbo.2026.100751_b0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.02.002","article-title":"Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer","volume":"44","author":"Vignani","year":"2016","journal-title":"Cancer Treat. Rev."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:44:04Z","timestamp":1777625044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137426000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S2212137426000138"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100751","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100751"}}